Celltium Technologies Ltd. is at the forefront of personalized biotechnology. Their innovative scientific advances focus on developing groundbreaking, first-in-class curative therapies for major neurological disorders. Specifically, they specialize in creating treatments for conditions such as Charcot-Marie-Tooth disease (CMT), diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), and amyotrophic lateral sclerosis (ALS). These therapies address critical unmet needs in the field of neurology.

Vision and Mission: Celltium aspires to inspire a world without diseases and disabilities. Their mission is to lead in the field of biotechnology by developing innovative First-in-Class therapies for major neurological conditions. They aim to transform treatment paradigms, establish new standards in biotech-based medical solutions, and restore meaningful lives for patients with neurological disorders.

Noteworthy Points:

• Founded in 2020, Celltium is a biotechnology company based in Gyeonggi-do, South Korea.
• Their focus includes Charcot-Marie-Tooth disease, a rare genetic disorder affecting peripheral nerves, and other related conditions.
• Celltium’s commitment to groundbreaking therapies sets them apart in the field of neurology.